Guangzhou Vesber Biotechnology Co., Ltd. is a national high-tech enterprise focusing on the research, development, production and sales of innovative ophthalmology products. The main products include folding artificial vitreous balloon, folding top pressure balloon and myopic scleral reinforcement system. Among them, the representative product Foldable Capsular Vitreous Body (FCVB) is the world’s first artificial organ to save the eyeball. It can accurately simulate the structure and function of the human eye vitreous body, and was selected by the Ministry of Science and Technology in the 2018 Medical Device Innovation Product Catalog. In the review of the 40th anniversary of reform and opening up, it was listed as a typical example of “Made in China” to “Created in China”. The product has also received funding from the 863 project of the Ministry of Science and Technology and the 12th Five-Year Science and Technology Support Program. It has 22 patents in China, the United States, Russia, Australia and Japan.

After obtaining the medical device registration certificate of the People’s Republic of China, the company has carried out artificial vitreous implantation operations across the country, covering more than 40 regions including Guangdong, Beijing and Shanghai. Obtained the CE certificate and ISO13485 certificate issued by SGS, obtained the certification of the European Union, and successfully carried out clinical application and extensive sales in the United Kingdom, Belgium, Greece, Turkey, Russia and other countries.

The company is located in the Guangdong Medical Valley Industrial Park, Nansha District, the core area of ​​the Guangdong-Hong Kong-Macao Greater Bay Area, with a total of six floors and an area of ​​more than 5,000 square meters. It has 10,000-level clean workshops, Vesber Research Institute, Vesber Engineering Center, and clinical training center. As of 2019, it has obtained investments from a number of state-owned enterprises (Yueke, Kaide) and GEM listed companies (Opcom).